01093nas a2200229 4500000000100000008004100001260001200042653001200054653002200066653001200088653002200100653002000122100002100142700002100163700001900184245012300203856008300326300000800409490000700417520042500424022001400849 2024 d c04/202410aDapsone10aImmunosuppression10aleprosy10aLeprosy reactions10aPJP prophylaxis1 aRamírez-Perea N1 aMoran-Castaño C1 aPerez-Molina J00aShould prophylaxis against Pneumocystis jirovecii pneumonia be considered in selected patients with leprosy reactions? uhttps://pneumonia.biomedcentral.com/counter/pdf/10.1186/s41479-024-00127-x.pdf a1-30 v163 a

Leprosy reactions often require prolonged high-dose steroids or immunosuppressive drugs, putting patients at risk of Pneumocystis jirovecii pneumonia (PJP). However, no PJP cases are reported, possibly due to dapsone treatment for leprosy. In patients with leprosy reactions not receiving dapsone because of toxicity or resistance and requiring long-term immunosuppression, PJP prophylaxis should be considered.

 a2200-6133